The Efficacy of Different Treatment Options in Cutaneous Sarcoidosis: A Meta-analysis of RCTs
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0490Keywords:
cutaneous sarcoidosis, meta-analysis, randomized controlled trials, dermatology, immunomodulation, sarcoidosisAbstract
Cutaneous sarcoidosis is a granulomatous skin disease associated with significant quality-of-life impairment. Evidence from randomized controlled trials (RCTs) guiding systemic or targeted therapy remains limited. To assess the efficacy and safety of pharmacological therapies for cutaneous sarcoidosis in randomized placebo-controlled trials PubMed, the Cochrane Library, and ClinicalTrials.gov were searched through January 2025. Eligible studies were RCTs including adults with cutaneous sarcoidosis randomized to pharmacological therapy versus placebo. Outcomes were clinical response, quality of life, and serious adverse events (SAEs). Pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were calculated using random-effects models. Six RCTs including 156 participants were analyzedanalysed. Pharmacological therapies did not significantly improve clinical response compared with placebo (OR 2.24; 95% CI, 0.73–6.90; p=0.16). A non-significant trend toward improved quality of life was observed (OR 2.23; 95% CI, 0.87–5.73; p=0.09). No significant difference in SAEsserious adverse events was found between groups (OR 0.97; 95% CI, 0.48–1.96; p=0.93). Risk of bias ranged from moderate to high, with low statistical heterogeneity. Pharmacological add-on therapies showed no significant efficacy beyond corticosteroids but may improve quality of life. Larger, well-designed RCTs are needed.
Downloads
References
English JC, Patel PJ, Greer KE. Sarcoidosis. J Am Acad Dermatol 2001; 44: 725–743. DOI: https://doi.org/10.1067/mjd.2001.114596
Yanardag H, Tetikkurt C, Bilir M, Demirci S, Iscimen A. Diagnosis of cutaneous sarcoidosis; clinical and the prognostic significance of skin lesions. Multidiscip Respir Med 2013; 8: 26. DOI: https://doi.org/10.1186/2049-6958-8-26
Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357: 2153–2165. DOI: https://doi.org/10.1056/NEJMra071714
Neves FS, Pereira IA, Sztajnbok F, Neto NSR. Sarcoidosis: a general overview. Adv Rheumatol 2024; 64: 57. DOI: https://doi.org/10.1186/s42358-024-00381-z
Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet 2014; 383: 1155–1167. DOI: https://doi.org/10.1016/S0140-6736(13)60680-7
Lodha S, Sanchez M, Prystowsky S. Sarcoidosis of the skin: a review for the pulmonologist. Chest 2009; 136: 583–596. DOI: https://doi.org/10.1378/chest.08-1527
Mañá J, Marcoval J, Graells J, Salazar A, Peyrí J, Pujol R. Cutaneous involvement in sarcoidosis. Relationship to systemic disease. Arch Dermatol 1997; 133: 882–888. DOI: https://doi.org/10.1001/archderm.1997.03890430098013
Koneti J, Cherukuri SP, Gadde S, Kalluru R, Chikatimalla R, Dasaradhan T. Sarcoidosis and its dermatological manifestations: a narrative review. Cureus 2022; 14: e28053. DOI: https://doi.org/10.7759/cureus.28053
Ruocco E, Gambardella A, Langella GG, Lo Schiavo A, Ruocco V. Cutaneous sarcoidosis: an intriguing model of immune dysregulation. Int J Dermatology 2015; 54: 1–12. DOI: https://doi.org/10.1111/ijd.12566
Baughman RP, Judson MA, Lower EE, Drent M, Costabel U, Flavin S, et al. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis 2016; 32: 289–295.
Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2013; 68: 765–773. DOI: https://doi.org/10.1016/j.jaad.2012.10.056
Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 2014; 44: 1296–1307. DOI: https://doi.org/10.1183/09031936.00000914
Droitcourt C, Rybojad M, Porcher R, Juillard C, Cosnes A, Joly P, et al. A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. Chest 2014; 146: 1046–1054. DOI: https://doi.org/10.1378/chest.14-0015
Redl A, Doberer K, Unterluggauer L, Kleissl L, Krall C, Mayerhofer C, et al. Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial. Lancet Rheumatol 2024; 6: e81–e91. DOI: https://doi.org/10.1016/S2665-9913(23)00302-8
Drake WP, Oswald-Richter K, Richmond BW, Isom J, Burke VE, Algood H, et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol 2013; 149: 1040–1049. DOI: https://doi.org/10.1001/jamadermatol.2013.4646
Sandbank S, Molho-Pessach V, Farkas A, Barzilai A, Greenberger S. Oral and topical sirolimus for vascular anomalies: a multicentre study and review. Acta Derm Venereol 2019; 99: 990–996. DOI: https://doi.org/10.2340/00015555-3262
Zhang Z, Li Y, Zhang G, Yang K, Qiu T, Zhou J, et al. Safety evaluation of oral sirolimus in the treatment of childhood diseases: a systematic review. Children 2022; 9: 1295. DOI: https://doi.org/10.3390/children9091295
Saketkoo LA, Russell AM, Jensen K, Mandizha J, Tavee J, Newton J, et al. Health-related quality of life (HRQoL) in sarcoidosis: diagnosis, management, and health outcomes. Diagnostics 2021; 11: 1089. DOI: https://doi.org/10.3390/diagnostics11061089
Obi ON, Saketkoo LA, Russell AM, Baughman RP. Sarcoidosis: updates on therapeutic drug trials and novel treatment approaches. Front Med 2022; 9. DOI: https://doi.org/10.3389/fmed.2022.991783
Nelson NC, Kogan R, Condos R, Hena KM. Emerging therapeutic options for refractory pulmonary sarcoidosis: the evidence and proposed mechanisms of action. JCM 2023; 13: 15. DOI: https://doi.org/10.3390/jcm13010015
Talty R, Damsky W, King B. Treatment of cutaneous sarcoidosis with tofacitinib: a case report and review of evidence for Janus kinase inhibition in sarcoidosis. JAAD Case Rep 2021; 16: 62–64. DOI: https://doi.org/10.1016/j.jdcr.2021.08.012
Friedman MA, Le B, Stevens J, Desmarais J, Seifer D, Ogle K, et al. Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study. Lung 2021; 199: 147–153. DOI: https://doi.org/10.1007/s00408-021-00436-8
Safadi M, Whittington K, Zahner S, Rubinstein I, Tsoukas M, Sweiss N. Recalcitrant cutaneous sarcoidosis treated with upadacitinib: case report. JAAD Case Rep 2024; 51: 7–9. DOI: https://doi.org/10.1016/j.jdcr.2024.06.019
McGuire L, Brown R, Asimaki A. Use of sirolimus, an mTOR inhibitor, to treat sarcoidosis in multiple systems. J Cardiovasc Transl Res 2025; 18: 1893–1901. DOI: https://doi.org/10.1007/s12265-025-10700-4
Dhooria S. Five principles and protocols for the clinician based on the 2021 ERS and BTS statements for treating sarcoidosis. Lung India 2024; 41: 459–463. DOI: https://doi.org/10.4103/lungindia.lungindia_499_24
Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021; 58: 2004079. DOI: https://doi.org/10.1183/13993003.04079-2020
Starshinova A, Berg E, Rubinstein A, Kulpina A, Kudryavtsev I, Kudlay D. Chronic sarcoidosis: diagnostic difficulties and search for new criteria of inflammatory activity (a case report and literature review). JCM 2024; 13: 6974. DOI: https://doi.org/10.3390/jcm13226974
Sun J, Liu T, Yan Y, Huo K, Zhang W, Liu H, et al. The role of Th1/Th2 cytokines played in regulation of specific CD4 + Th1 cell conversion and activation during inflammatory reaction of chronic obstructive pulmonary disease. Scand J Immunol 2018; 88: e12674. DOI: https://doi.org/10.1111/sji.12674
Additional Files
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
